Theoretic criteria for antibody penetration into solid tumors and micrometastases

Journal of Nuclear Medicine

Volumn 48, Issue 6, 2007, Pages 995-999

  Thurber, Greg M ^a   Zajic, Slelan C ^a   Wittrup, K Dane ^a,b  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Biodistribution; Molecular imaging; Monoclonal antibodies; Penetration; Pharmacokinetics; Radionuclide therapy

Indexed keywords

MONOCLONAL ANTIBODY; RADIOISOTOPE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ARTICLE; BLOOD VESSEL PERMEABILITY; CAPILLARY; CATABOLISM; DIFFUSION; DRUG CLEARANCE; EXTRAVASATION; HUMAN; INTERNALIZATION; KINETICS; MICROMETASTASIS; MOLECULAR IMAGING; PLASMA CLEARANCE; PRIORITY JOURNAL; SOLID TUMOR; TUMOR VASCULARIZATION;

ANTIBODIES; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; NEOPLASMS;

EID: 34250380650     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.106.037069     Document Type: Article

References (15)

1. Jain RK. Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng. 1999;01:241-263.
2. van Osdol W, Fujimori K, Weinstein J. An analysis of monoclonal antibody distribution in microscopic tumor nodules: consequences of a "binding site barrier." Cancer Res. 1991;51:4776-4784.
3. Graff C, Wittrup KD. Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res. 2003;63:1288-1296.
4. Austin C, Maziere A, Pisacane P, et al. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trasluzumab and geldanamycin. Mol Biol Cell. 2004;15:5268-5282.
5. Baulida J, Kraus MH, Alimandi M, DiFiore PP, Carpenter G. All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J Biol Chem. 1996;271:5251-5257.
6. Kyriakos R, Shih L, Ong G, Patel K, Goldenberg D, Mattes MJ. The fate of antibodies bound to the surface of tumor cells in vitro. Cancer Res. 1992;52: 835-842.
7. Mattes MJ, Griffiths G, Diril H, Goldenberg D, Ong G, Shih L. Processing of antibody-radioisotope conjugates after binding to the surface of tumor cells. Cancer. 1994;73:787-793.
8. Gerlowski L, Jain RK. Microvascular permeability of normal and neoplastic tissues. Microvasc Res. 1986;31:288-305.
9. Baish J, Gazit Y, Berk D, Nozue M, Baxter L, Jain RK. Role of tumor vascular architecture in nutrient and drug delivery: an invasion percolation-based network model. Microvasc Res. 1996;51:327-346.
10. Adams G, Schier R, McCall A, et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res. 2001;61: 4750-4755.
11. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin (TM)) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 1998;58:2825-2831.
12. Press OW, Shan D, Howell Clark J, et al. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res. 1996;56:2123-2129.
13. Wenning LA, Murphy RM. Coupled cellular trafficking and diffusional limitations in delivery of immunotoxins to multicell tumor spheroids. Biotechnol Bioeng. 1999;62:562-575.
14. McIntosh D, Tan X, Oh P, Schnitzer J. Targeting endothelium and its dynamic caveolae for tissue-specific transcytosis in vivo: a pathway to overcome cell barriers to drug and gene delivery. Pro Natl Acad Sci U S A. 2002;99:1996-2001.
15. Koppe MJ, Bleichrodt RP, Oyen WJG, Boerman OC. Radioimmunotherapy and colorectal cancer. Br J Surg. 2005;92:264-276.